2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Arch Med Sci 2023;19(6)

Enlaces

https://doi.org/10.5114/aoms/174743w

Artículos Relacionadas

Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes

ESPEN practical guideline on clinical nutrition in acute and chronic pancreatitis

New therapies for obesity

Postmenopausal Osteoporosis

EMAS position statement: Testosterone replacement therapy in older men

A literature review of evidence for primary prevention of overweight and obesity in healthy weight children and adolescents: A report produced by a working group of the Danish Council on Health and Disease Prevention

Children and adolescents in the Amsterdam Cohort of Gender Dysphoria: trends in diagnostic- and treatment trajectories during the first 20 years of the Dutch Protocol

The Syndrome of Inappropriate Antidiuresis List of authors.

Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes

European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors

Agenda

Abril 2024

Lun	Mar	Mié	Jue	Vie	Sáb	Dom
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	1	2	3	4	5

Top